Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study
暂无分享,去创建一个
Ke-Feng Wang | Z. Xia | Jia-yu Zhu | Xiaoqin Chen | Hua Wang | Zhi-Jun Wuxiao | Jiayu Zhu | Zhihui Wang | Su Li | Yue Lu | Zhong-Jun Xia | Yue Lu | Xiaoqin Chen | Zhi-jun Wuxiao | Su Li | Zhi-hui Wang | Hua Wang | Kefeng Wang
[1] D. Weisenburger,et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. , 2009, Blood.
[2] W. Wilson,et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Y. Xia,et al. First‐line combination of gemcitabine, oxaliplatin, and L‐asparaginase (GELOX) followed by involved‐field radiation therapy for patients with stage IE/IIE extranodal natural killer/T‐cell lymphoma , 2013, Cancer.
[4] Z. Zhan,et al. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. , 1995, Blood.
[5] Y. Kwong,et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Wen-Qi Jiang,et al. Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma , 2012, Annals of Hematology.
[7] S. Song,et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] S. Bates,et al. P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines , 1991, International journal of cancer.
[9] C. Tzeng,et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Jordi Martínez,et al. GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study , 2007, European journal of haematology.
[11] K. Gatter,et al. Mature T and NK Cell Neoplasms , 2014 .
[12] J. Roh,et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Q. Cai,et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience , 2011, Leukemia & lymphoma.
[15] J. Chan,et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. , 2002, International journal of radiation oncology, biology, physics.
[16] Keunchil Park,et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Bo Xu,et al. L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type , 2009, Annals of Hematology.
[18] A. Bleyer,et al. Phase II study of oxaliplatin in patients with recurrent or refractory non‐Hodgkin lymphoma , 2005, Cancer.
[19] Biyun Wang,et al. Immunohistochemical expression and clinical significance of P‐glycoprotein in previously untreated extranodal NK/T‐cell lymphoma, nasal type , 2008, American journal of hematology.
[20] J. Roh,et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. , 2004, International journal of radiation oncology, biology, physics.
[21] S. Hsu,et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T‐cell or T‐cell lymphoma , 2004, Cancer.
[22] W. Lee,et al. Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma , 2009, The Korean journal of internal medicine.
[23] Jun Zhu,et al. Midline NK/T‐cell lymphoma nasal‐type: treatment outcome, the effect of L‐asparaginase based regimen, and prognostic factors , 2006, Hematological oncology.
[24] G. Trabucchi,et al. L-asparaginase treatment. , 1971 .
[25] S. Pileri,et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. , 2010, Pathologica.
[26] N. Lee,et al. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia , 2006, Leukemia & lymphoma.
[27] Y. Kwong,et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. , 2012, Blood.
[28] Jiade J Lu,et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity , 2007, Leukemia & lymphoma.
[29] M. Lim,et al. Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms , 2009, Journal of hematopathology.
[30] W. Wilson,et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Weisenburger,et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] H. Y. Seo,et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. , 2006, Leukemia & lymphoma.
[33] Jiade J Lu,et al. Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma , 2009, Clinical Cancer Research.
[34] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[35] Ji Yeun Kim,et al. Therapeutic Outcome of Extranodal NK/T-Cell Lymphoma Initially Treated with Chemotherapy Result of Chemotherapy in NK/T-Cell Lymphoma , 2003, Acta oncologica.
[36] P. Gaulard,et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. , 2011, Blood.
[37] R. Millikan,et al. Gemcitabine modulation of alkylator therapy , 2001, Cancer.
[38] Shulian Wang,et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] E. Raymond,et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.